Vascular CT contrast agent development
血管CT造影剂开发
基本信息
- 批准号:10251468
- 负责人:
- 金额:$ 84.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAlgorithmsAmericanAngiographyAnimal ModelAnimalsAppearanceAtherosclerosisAwardBiologicalBloodBlood VesselsBody mass indexCanis familiarisCardiovascular DiseasesCharacteristicsClinicalClinical TrialsColorContrast MediaDataDevelopmentDistantDocumentationDoseDrug KineticsEffectivenessExcretory functionFormulationFrequenciesGoalsHumanHypersensitivityImageImplantIn VitroIndustryInjectionsInjury to KidneyIntercellular FluidIntraperitoneal InjectionsIntravenousIodineKidneyMetalsMethodsModalityMorphologic artifactsObesityOperative Surgical ProceduresOrganPatient imagingPatientsPhasePhase II/III TrialPlasmaPopulationPrevalenceProcessPropertyRadiology SpecialtyRattusRecoveryReproducibilityResearchResearch PersonnelRiskRoentgen RaysRouteSafetySalesScanningSeveritiesSignal TransductionSmall Business Innovation Research GrantStentsStructureTantalumTestingTimeTissuesToxic effectToxicity TestsTrauma patientVascular DiseasesVascular calcificationVenousWorkX-Ray Computed Tomographyabsorptionacute toxicitybasebiomaterial compatibilitycardiovascular risk factorclinical translationcommercializationcontrast enhancedcontrast imagingdrug developmentefficacy testingexperienceextracellularfirst-in-humangood laboratory practiceimaging capabilitiesimprovedin vivointraperitonealmetallicitynanoparticleobese patientsobese personpatient populationphase 1 testingpre-clinicalpreclinical safetypreclinical toxicityprototyperisk minimizationsafety testingscale upsmall moleculestability testingvolunteer
项目摘要
Project Summary / Abstract
Our long-term goal is to revolutionize the effectiveness of vascular imaging by computed tomography (CT) for
millions of Americans. Contrast-enhanced CT is the modality of choice for imaging many forms of vascular
disease due to ease of use and wide availability. Unfortunately, currently available CT contrast agents are
severely limited by poor vascular enhancement, particularly in large-to-obese patients because of beam
hardening and loss of signal at the high kVp settings needed to image this patient population. Moreover, these
so-called “extravascular extracellular” small-molecule agents equilibrate rapidly between the intravascular and
interstitial fluid, and hence provide a “washed out” appearance of critical venous structures. Considering that
obesity is a major risk factor for cardiovascular disease and is increasing in prevalence, a transformative
contrast agent with improved imaging capabilities is urgently needed for this poorly served population. Patients
with an allergy to iodine are without alternative CT contrast options. Furthermore, iodine contrast is poorly
distinguished from vascular calcifications and metal-containing implants such as stents, despite the advent of
dual energy CT.
We propose to develop a safe blood pool tantalum nanoparticle contrast agent (TaCZ) to address these
urgent unmet clinical needs. Our prior work showed excellent tolerance to TaCZ in four animal species, even
up to 6X intended clinical dose and with repeat dosing. TaCZ shows superior X-ray signal in vivo and in vitro,
even in simulated large body habitus. TaCZ shows the unique property of having both a blood pool distribution
yet, surprisingly, rapid renal excretion and minimal biological retention on par with clinical iodinated contrast
agents. With advanced metal artifact reduction algorithms for CT imaging, TaCZ is unlike iodinated agents in
that it retains excellent signal, which makes it ideal for imaging post-surgical or trauma patients. The duration
of intense vascular enhancement is over 5 minutes, unlike for iodinated agents’ 5 to 10 seconds, which
minimizes risk for error and mis-timing at vascular imaging. Profoundly, TaCZ may be used simultaneously
with iodine contrast agents as different “colors” at dual energy CT imaging to generate unprecedented
information-rich co-registered color contrast CT images with a single 5 second pass of the scanner. In our
project proposal, we will define processes and specifications for scaled-up TaCZ synthesis for tight size
distribution. Preclinical toxicity data will be extended to include maximum feasible intraperitoneal and GLP
maximum intravenous repeat dose testing to enable FDA-IND. Then first-in-human Clinical Phase 1 testing will
assess safety and efficacy in normal and obese individuals. At the conclusion of this project, we will have
validated data suitable for the Clinical Phase 2 and 3 human trials required for FDA-NDA approval and
commercial use of this transformative CT contrast agent.
项目总结/摘要
我们的长期目标是通过计算机断层扫描(CT)彻底改变血管成像的有效性,
数百万美国人。对比增强CT是对多种形式的血管病变进行成像的首选方式。
由于使用方便和广泛的可用性。不幸的是,目前可用的CT造影剂是
严重受限于较差的血管增强,特别是在大到肥胖的患者中,
在对该患者人群成像所需的高kVp设置下,信号硬化和丢失。而且这些
所谓的“血管外细胞外”小分子试剂在血管内和
间质液,并因此提供关键静脉结构的“洗出”外观。考虑到
肥胖是心血管疾病的一个主要危险因素,
对于这种服务不足的人群,迫切需要具有改进的成像能力的造影剂。患者
对碘过敏的患者没有替代的CT造影剂选择。此外,碘造影剂是差的,
与血管钙化和含金属植入物(如支架)不同,
双能CT
我们建议开发一种安全的血池钽纳米颗粒造影剂(TaCZ),以解决这些问题。
未满足的临床需求。我们先前的工作表明,四种动物对TaCZ具有极好的耐受性,
高达6倍预期临床剂量和重复给药。TaCZ在体内和体外均显示出良好的上级X射线信号,
即使是在模拟的大体型中。TaCZ显示出具有血池分布的独特性质,
然而,令人惊讶的是,与临床碘化造影剂相当的快速肾排泄和最小的生物保留
剂.利用先进的CT成像金属伪影减少算法,TaCZ与碘化剂不同,
它保留了出色的信号,这使得它成为手术后或创伤患者成像的理想选择。持续时间
强烈的血管增强超过5分钟,不像碘化剂的5到10秒,
最大限度地降低血管成像时的错误和误时风险。TaCZ可以同时用于
碘造影剂作为不同的“颜色”在双能CT成像,以产生前所未有的
信息丰富的共配准彩色对比CT图像,扫描仪单次扫描5秒。在我们
项目建议书,我们将确定工艺和规格,为规模扩大TaCZ合成紧凑的大小
分布临床前毒性数据将扩展至包括最大可行的腹膜内和GLP
最大静脉内重复剂量测试,以使FDA-IND。然后首次在人体临床1期测试将
评估在正常和肥胖个体中的安全性和有效性。在该项目结束时,我们将拥有
FDA-NDA批准所需的适用于临床2期和3期人体试验的验证数据,
这种变革性CT造影剂的商业用途。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael A Davis其他文献
Pre-Operative Simultaneous Fractionated Cisplatin and Radiation Therapy in the Treatment of Advanced Stage III and IV Squamous Cell Carcinoma of the Base of Tongue and Hypopharynx
术前同步分次顺铂和放射治疗治疗晚期舌根部和下咽部鳞状细胞癌
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:0
- 作者:
J. Tyrrell;Michael A Davis;G. Slotman - 通讯作者:
G. Slotman
Michael A Davis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael A Davis', 18)}}的其他基金
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 84.36万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 84.36万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 84.36万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 84.36万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 84.36万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 84.36万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 84.36万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 84.36万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 84.36万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 84.36万 - 项目类别: